Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H27N3O3S |
| Molecular Weight | 413.533 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)NC1=CC=C2SC3=CC=CC=C3N(C(=O)CCN(CC)CC)C2=C1
InChI
InChIKey=PQXGNJKJMFUPPM-UHFFFAOYSA-N
InChI=1S/C22H27N3O3S/c1-4-24(5-2)14-13-21(26)25-17-9-7-8-10-19(17)29-20-12-11-16(15-18(20)25)23-22(27)28-6-3/h7-12,15H,4-6,13-14H2,1-3H3,(H,23,27)
| Molecular Formula | C22H27N3O3S |
| Molecular Weight | 413.533 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15798717
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15798717
Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine. It is used in Russia and some other Commonwealth of Independent States countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease. It is also indicated as a treatment of refractory tachycardia associated with Wolff–Parkinson–White syndrome.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0086001 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2538064 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Ethacyzin Approved UseUnknown |
|||
| Primary | Ethacyzin Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
63.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32146624/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHACIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
571.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32146624/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHACIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32146624/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHACIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.rlsnet.ru/tn_index_id_5522.htm
The initial dose is 50 mg (1 table) 2-3 times a day. In case of insufficient clinical effect, the dose is increased (under compulsory ECG monitoring) to 50 mg 4 times a day (200 mg) or 100 mg 3 times daily (300 mg).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6882907
Ethacizine applied in the concentration range between 1 X 10(-7) and 1 X 10(-5) g/ml decreased the rate of action potential growth (Vmax) of the mammal myocardium. Inhibition of the Vmax was accompanied by the diminution of the force of contraction which involved two phases. Ethacizine also decreased the overshoot of slow response action potential with the time constant similar to that in the first rapid phase of force reduction.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:15:10 GMT 2025
by
admin
on
Mon Mar 31 19:15:10 GMT 2025
|
| Record UNII |
FE5SPV1Z6G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QC01BC09
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
||
|
WHO-ATC |
C01BC09
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
621878
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
107841
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
4835
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
100000126035
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
33414-33-4
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
FE5SPV1Z6G
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
Ethacizine
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
SUB32872
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
C046818
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
DTXSID50187057
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
CHEMBL1997663
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY | |||
|
DB13645
Created by
admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |